Page 139 - ESHRE2019

ALLOGENEIC iPSC GENERATION FROM CORD BLOOD UNITSWITH FREQUENTHLA HAPLOTYPES HO M O ZI G O TES ( I PS- PA N I A )
Call: RETOSCOLABORACION 2017
Principal aim: Development of an allogenic clinical grade hiPSC bank from HLA-homozygous cord blood from most frequent haplotypes with the aim to offer cell lines for basic research and clinical trials for cell therapy and clinical application
i. Ethical review of new contact with donors and the new therapeutic uses of donated cells
ii. Creation, characterization and validation of a registry of cord blood units with the HLAs most represented in the population of our geographical area.
iii. Definition of selection criteria and contact with 7 donors with HLA prevalent iv. Reprogramming of 7 cord blood units: creation of the active principle.
v. Expansion of 7 iPSC lines under GMPconditions: creation and registration of Master Cell Bank
vi. Expansion of 7 iPSC lines under GMP conditions: creation of Working Cell Bank and offer it for clinical trials
PCC Stem Cells - ESHRE Vienna 2019
Banc de Sang i Teixits (BST)
Centre of Regenerative Medicine in Barcelona (CMRB)
Subcontracted: Organización Nacional de Trasplantes (Spanish National Trasplant Organization)
Cord Blood Banks of Plan Nacional de Sangre de Cordón Umbilical (National Umbilical Cord Blood Plan)
Conclusions
• hPSC are already being generated with clinical grade standards under GMP conditions
• Few GMP hPSC lines available
• hPSC clinical trials are in progress for Macular degeneration, Parkinson disease,
Heart failure, Spinal cord injury and cancer both with hESC and hiPSC
PCC Stem Cells - ESHRE Vienna 2019
134
PRECONGRESS COURSE 13 I VIENNA, AUSTRIA – 23 JUNE 2019 137